CN111529708A - 用于预防和治疗与c1酯酶抑制剂缺乏相关的病症的c1-inh组合物和方法 - Google Patents

用于预防和治疗与c1酯酶抑制剂缺乏相关的病症的c1-inh组合物和方法 Download PDF

Info

Publication number
CN111529708A
CN111529708A CN202010362851.6A CN202010362851A CN111529708A CN 111529708 A CN111529708 A CN 111529708A CN 202010362851 A CN202010362851 A CN 202010362851A CN 111529708 A CN111529708 A CN 111529708A
Authority
CN
China
Prior art keywords
leu
esterase inhibitor
composition
ser
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010362851.6A
Other languages
English (en)
Chinese (zh)
Inventor
C·加拉格尔
S·卢迪
M·C·曼宁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Weiluo Pharmaceutical Biological Preparation Co ltd
Original Assignee
Viropharma Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51538486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN111529708(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Viropharma Holdings Ltd filed Critical Viropharma Holdings Ltd
Publication of CN111529708A publication Critical patent/CN111529708A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN202010362851.6A 2013-03-15 2014-03-17 用于预防和治疗与c1酯酶抑制剂缺乏相关的病症的c1-inh组合物和方法 Pending CN111529708A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361791399P 2013-03-15 2013-03-15
US61/791,399 2013-03-15
CN201480014712.7A CN105517559A (zh) 2013-03-15 2014-03-17 用于预防和治疗与c1酯酶抑制剂缺乏相关的病症的c1-inh组合物和方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480014712.7A Division CN105517559A (zh) 2013-03-15 2014-03-17 用于预防和治疗与c1酯酶抑制剂缺乏相关的病症的c1-inh组合物和方法

Publications (1)

Publication Number Publication Date
CN111529708A true CN111529708A (zh) 2020-08-14

Family

ID=51538486

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010362851.6A Pending CN111529708A (zh) 2013-03-15 2014-03-17 用于预防和治疗与c1酯酶抑制剂缺乏相关的病症的c1-inh组合物和方法
CN201480014712.7A Pending CN105517559A (zh) 2013-03-15 2014-03-17 用于预防和治疗与c1酯酶抑制剂缺乏相关的病症的c1-inh组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480014712.7A Pending CN105517559A (zh) 2013-03-15 2014-03-17 用于预防和治疗与c1酯酶抑制剂缺乏相关的病症的c1-inh组合物和方法

Country Status (30)

Country Link
US (9) US9616111B2 (cg-RX-API-DMAC7.html)
EP (3) EP3290046B1 (cg-RX-API-DMAC7.html)
JP (9) JP6184581B2 (cg-RX-API-DMAC7.html)
KR (4) KR102579789B1 (cg-RX-API-DMAC7.html)
CN (2) CN111529708A (cg-RX-API-DMAC7.html)
AU (3) AU2014232912A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015023207A8 (cg-RX-API-DMAC7.html)
CA (2) CA3054718A1 (cg-RX-API-DMAC7.html)
CY (2) CY1119419T1 (cg-RX-API-DMAC7.html)
DE (1) DE202014011208U1 (cg-RX-API-DMAC7.html)
DK (2) DK2968434T3 (cg-RX-API-DMAC7.html)
EA (1) EA201591278A1 (cg-RX-API-DMAC7.html)
ES (2) ES2713004T3 (cg-RX-API-DMAC7.html)
GB (1) GB2530921B (cg-RX-API-DMAC7.html)
HK (1) HK1250912B (cg-RX-API-DMAC7.html)
HR (2) HRP20171269T1 (cg-RX-API-DMAC7.html)
HU (2) HUE041837T2 (cg-RX-API-DMAC7.html)
IL (2) IL241549B (cg-RX-API-DMAC7.html)
LT (2) LT2968434T (cg-RX-API-DMAC7.html)
ME (2) ME02865B (cg-RX-API-DMAC7.html)
MX (3) MX373965B (cg-RX-API-DMAC7.html)
PL (2) PL2968434T3 (cg-RX-API-DMAC7.html)
PT (2) PT3290046T (cg-RX-API-DMAC7.html)
RS (2) RS56285B1 (cg-RX-API-DMAC7.html)
SG (2) SG11201507616VA (cg-RX-API-DMAC7.html)
SI (2) SI2968434T1 (cg-RX-API-DMAC7.html)
SM (2) SMT201900141T1 (cg-RX-API-DMAC7.html)
TR (1) TR201900319T4 (cg-RX-API-DMAC7.html)
WO (1) WO2014145519A2 (cg-RX-API-DMAC7.html)
ZA (3) ZA201507604B (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02865B (me) 2013-03-15 2018-04-20 Shire Viropharma Inc C1-inh kompozicije za upotrebu u prevenciji i liječenju naslednog angioedema (hae)
ME03318B (me) 2013-11-22 2019-10-20 Shire Viropharma Inc Postupci lečenja odbacivanja posredovanog antitelima pacijenata sa transplatiranim organom sa inhibitorom c1-esteraze
WO2016131958A1 (en) * 2015-02-20 2016-08-25 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
CN113999875A (zh) * 2015-05-28 2022-02-01 康奈尔大学 腺相关病毒介导的c1ei递送作为用于血管性水肿的疗法
CN108463243B (zh) * 2015-11-19 2022-06-14 夏尔人类遗传性治疗公司 重组人c1酯酶抑制剂及其用途
CN109562149A (zh) * 2016-08-05 2019-04-02 德国杰特贝林生物制品有限公司 C1酯酶抑制剂的药物制剂
AU2017316513A1 (en) * 2016-08-23 2019-03-28 Csl Behring Gmbh Method of preventing acute attacks of hereditary angioedema associated with C1 esterase inhibitor deficiency
CA3061279A1 (en) 2017-05-16 2018-11-22 Octapharma Ag C1-esterase inhibitor preparation
BR112020017626A2 (pt) 2018-02-28 2020-12-22 Pharming Intellectual Property B.V. Tratamento e prevenção de pré-eclâmpsia
WO2019166572A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
AU2019288683A1 (en) 2018-06-22 2021-01-21 Junten Bio Co., Ltd. Antibody capable of inducing immune tolerance produced using cell mixture having complexed state, and induced lymphocyte or cell therapeutic agent and cell therapy method each using induced lymphocyte
TWI832868B (zh) 2018-06-22 2024-02-21 日商順天生化股份有限公司 用於誘發感染性免疫耐受之組合物
US12139537B2 (en) 2018-06-22 2024-11-12 Junten Bio Co., Ltd. Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte
CN114786724A (zh) * 2019-12-16 2022-07-22 尼普洛株式会社 防聚集剂以及使用该防聚集剂的药物组合物和医疗用设备
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
CN117120076A (zh) * 2021-01-27 2023-11-24 斯帕克治疗公司 用于治疗遗传性血管性水肿的组合物和方法
JP2024525084A (ja) 2021-07-09 2024-07-09 ファーミング・インテレクチュアル・プロパティー・ビー.ブイ. C1エステラーゼ阻害剤によるウイルス感染関連症状の治療
KR20230046146A (ko) 2021-09-29 2023-04-05 주식회사 엘지에너지솔루션 배터리 제어 시스템 및 방법
WO2025090843A1 (en) * 2023-10-27 2025-05-01 Kansas State University Research Foundation Small-molecule inhibitors of c1s protease and classical complement pathway
CN119823254B (zh) * 2025-03-14 2025-06-03 深圳市卫光生物制品股份有限公司 一种c1酯酶抑制剂重组变体及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101365478A (zh) * 2005-12-21 2009-02-11 法明知识产权股份有限公司 C1抑制剂在预防缺血-再灌注损伤中的应用
WO2013013017A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
CN104080474A (zh) * 2011-12-22 2014-10-01 德国杰特贝林生物制品有限公司 C1-抑制剂在治疗中枢神经系统继发性水肿中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304482A (en) 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
WO1992022320A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
EP0716611B1 (en) * 1993-09-01 2002-02-06 Stichting Sanquin Bloedvoorziening C1-esterase inhibitor to reduce myocardial injury during acute myocardial infarction
EP0868191A1 (en) 1995-12-18 1998-10-07 Stichting Sanquin Bloedvoorziening Potentiation of complement and coagulation inhibitory properties of c1-inhibitor.
AT409336B (de) 1999-12-22 2002-07-25 Baxter Ag Verfahren zur herstellung einer c1-esterase-inhibitor (c1-inh)-hältigen zusammensetzung
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
EP1252184B1 (en) 2000-01-31 2008-01-02 Pharming Intellectual Property B.V. Human c1 inhibitor produced in the milk of transgenic mammals
DE60139944D1 (de) 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
DE10112617A1 (de) 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
WO2004034971A2 (en) 2002-09-25 2004-04-29 The Center For Blood Research, Inc. Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof
WO2004110356A2 (en) 2003-05-15 2004-12-23 Cbr Institute For Biomedical Research, Inc. Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity
US7544853B2 (en) 2003-05-16 2009-06-09 Pharming Intellectual Property B.V. C1 inhibitor with short half-life transient treatment
US20060233776A1 (en) 2003-08-19 2006-10-19 Norbert Heimburger C1-inh as a drug for treating viruses pathogenic to humans
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
EP1893227A2 (en) 2005-06-06 2008-03-05 Girish J. Kotwal Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
KR101126423B1 (ko) 2005-10-21 2012-07-11 카탈리스트 바이오사이언시즈, 인코포레이티드 보체 활성화를 억제하는 변형된 프로테아제
US8071532B2 (en) 2005-12-21 2011-12-06 Pharming Intellectual Property B.V. Use of C1 inhibitor for the prevention of ischemia-reperfusion injury
US7837992B2 (en) 2006-06-22 2010-11-23 Beth Israel Deaconess Medical Center C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
DK2109457T3 (en) 2007-02-12 2016-04-11 Csl Behring Gmbh THERAPEUTIC USE OF KAZAL TYPE SERINE PROTEASE INHIBITORS
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US8420081B2 (en) 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
US20100143325A1 (en) 2008-12-09 2010-06-10 Vascular Laboratory, Inc. Composition And Methods Involving Thrombolytic Agents
JP5871798B2 (ja) 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 肝再生を刺激する方法
EP3150635A3 (en) 2009-10-16 2017-06-21 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
AU2011222883B2 (en) 2010-03-05 2016-05-26 Omeros Corporation Chimeric inhibitor molecules of complement activation
WO2011116291A1 (en) * 2010-03-18 2011-09-22 Thrombolytic Science International Production of human c1 inhibitor in human cells
DK2758076T3 (en) 2011-09-24 2019-04-01 Csl Behring Gmbh COMBINATION THERAPY USING IMMUNOGLOBULIN AND C1 INHIBITOR
CA2867611A1 (en) 2012-03-16 2013-09-19 Belrose Pharma, Inc. Polymeric conjugates of c1-inhibitors
CA2902841A1 (en) 2013-03-13 2014-10-02 Creatics Llc Methods and compositions for detecting pancreatic cancer
ME02865B (me) * 2013-03-15 2018-04-20 Shire Viropharma Inc C1-inh kompozicije za upotrebu u prevenciji i liječenju naslednog angioedema (hae)
JP6935245B2 (ja) * 2017-06-29 2021-09-15 大和ハウス工業株式会社 収容ラック
JP6889626B2 (ja) * 2017-06-29 2021-06-18 トキコシステムソリューションズ株式会社 燃料供給システム

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101365478A (zh) * 2005-12-21 2009-02-11 法明知识产权股份有限公司 C1抑制剂在预防缺血-再灌注损伤中的应用
WO2013013017A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
CN104080474A (zh) * 2011-12-22 2014-10-01 德国杰特贝林生物制品有限公司 C1-抑制剂在治疗中枢神经系统继发性水肿中的应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CARTER,P.E. ET AL.: "GenBank:CAA30314", 《GENBANK:CAA30314》 *
无: "Lev公司开发的C1酯酶抑制剂产品Cinryze在美国获准上市", 《药学进展》 *
生物谷: "BIOONNEWS:森特贝林(CSL behring)启动C1酯酶抑制剂皮下给药研究", 《HTTPS://NEWS.BIOON.COM/ARTICLE/6550250.HTML》 *

Also Published As

Publication number Publication date
ZA201507604B (en) 2018-05-30
JP2021088599A (ja) 2021-06-10
TR201900319T4 (tr) 2019-02-21
LT3290046T (lt) 2019-03-12
RS56285B1 (sr) 2017-12-29
US10201595B2 (en) 2019-02-12
US20180110843A1 (en) 2018-04-26
BR112015023207A8 (pt) 2018-01-23
GB201519921D0 (en) 2015-12-23
KR20210129267A (ko) 2021-10-27
US20160015795A1 (en) 2016-01-21
HUE041837T2 (hu) 2019-05-28
AU2014232912A1 (en) 2015-09-03
JP6877470B2 (ja) 2021-05-26
US20190160157A1 (en) 2019-05-30
LT2968434T (lt) 2017-09-25
ZA201706929B (en) 2019-05-29
EP2968434A2 (en) 2016-01-20
IL241549B (en) 2020-08-31
US20180110844A1 (en) 2018-04-26
RS58351B1 (sr) 2019-03-29
JP6473535B2 (ja) 2019-02-20
PT2968434T (pt) 2017-09-18
DK3290046T3 (en) 2019-03-18
US10080788B2 (en) 2018-09-25
US11364288B2 (en) 2022-06-21
EP2968434A4 (en) 2016-03-02
CY1119419T1 (el) 2018-03-07
ES2713004T3 (es) 2019-05-17
EP2968434B1 (en) 2017-06-28
NZ751555A (en) 2021-07-30
HUE036224T2 (hu) 2018-06-28
MX2021011946A (es) 2021-11-17
JP2018119002A (ja) 2018-08-02
PL3290046T3 (pl) 2019-05-31
US20200261556A1 (en) 2020-08-20
GB2530921B (en) 2017-09-20
JP2018119001A (ja) 2018-08-02
ME03326B (me) 2019-10-20
US20190160158A1 (en) 2019-05-30
KR20150135242A (ko) 2015-12-02
JP2018119000A (ja) 2018-08-02
CA2904543C (en) 2019-10-08
KR20220070049A (ko) 2022-05-27
SMT201900141T1 (it) 2019-05-10
WO2014145519A2 (en) 2014-09-18
PL2968434T3 (pl) 2018-01-31
AU2020203183A1 (en) 2020-06-04
DK2968434T3 (en) 2017-09-11
KR20210021146A (ko) 2021-02-24
JP6184581B2 (ja) 2017-08-23
DE202014011208U1 (de) 2018-08-23
JP6877472B2 (ja) 2021-05-26
JP2019073544A (ja) 2019-05-16
MX373965B (es) 2020-07-13
AU2018229558A1 (en) 2018-10-04
EP3290046A1 (en) 2018-03-07
MX2020004724A (es) 2022-01-18
SMT201700415T1 (it) 2017-11-15
ME02865B (me) 2018-04-20
EA201591278A1 (ru) 2016-03-31
JP6422520B2 (ja) 2018-11-14
SI3290046T1 (sl) 2019-04-30
JP2016516073A (ja) 2016-06-02
NZ710730A (en) 2021-07-30
US10130690B2 (en) 2018-11-20
CY1121653T1 (el) 2020-07-31
CN105517559A (zh) 2016-04-20
KR102579789B1 (ko) 2023-09-15
US10105423B2 (en) 2018-10-23
BR112015023207A2 (pt) 2017-11-21
WO2014145519A3 (en) 2014-12-31
IL276153A (en) 2020-09-30
JP6473536B2 (ja) 2019-02-20
JP6877471B2 (ja) 2021-05-26
GB2530921A (en) 2016-04-06
PT3290046T (pt) 2019-02-18
CA3054718A1 (en) 2014-09-18
MX2015011281A (es) 2016-03-03
US20180085441A1 (en) 2018-03-29
US11534482B2 (en) 2022-12-27
SG10201707598QA (en) 2017-10-30
AU2018229558B2 (en) 2020-03-05
MX389449B (es) 2025-03-20
ES2639833T3 (es) 2017-10-30
ZA201806793B (en) 2020-01-29
HK1220403A1 (en) 2017-05-05
HRP20171269T1 (hr) 2017-11-03
US20180153972A1 (en) 2018-06-07
EP3290046B1 (en) 2019-01-02
US9616111B2 (en) 2017-04-11
AU2020203183B2 (en) 2022-06-02
JP2019073545A (ja) 2019-05-16
CA2904543A1 (en) 2014-09-18
JP6473534B2 (ja) 2019-02-20
HK1250912B (en) 2020-01-10
US20170224788A1 (en) 2017-08-10
JP2019073546A (ja) 2019-05-16
SI2968434T1 (sl) 2017-11-30
HRP20190270T1 (hr) 2019-04-05
KR102430453B1 (ko) 2022-08-05
SG11201507616VA (en) 2015-10-29
JP2017105847A (ja) 2017-06-15
IL276153B (en) 2022-06-01
EP3508213A1 (en) 2019-07-10

Similar Documents

Publication Publication Date Title
AU2020203183B2 (en) C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficiency
HK1250912A1 (en) C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency
HK40036345A (en) C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficiency
HK40010873A (en) C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency
HK1220403B (en) C1-inh compositions for use in the prevention and treatment of hereditary angioedema (hae).

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Massachusetts, USA

Applicant after: Charlotte Pharmaceutical Co.,Ltd.

Address before: Massachusetts, USA

Applicant before: VIROPHARMA HOLDINGS Ltd.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40036345

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210906

Address after: Massachusetts, USA

Applicant after: WeiLuo pharmaceutical biological preparation Co.,Ltd.

Address before: Massachusetts, USA

Applicant before: Charlotte Pharmaceutical Co.,Ltd.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20200814